Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 3 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.
Register Basic AccountSubscribe for an annual subscription for $359
Enjoy comprehensive and exclusive data you can't find elsewhere!
Subscribe for $359
Already have an account or paid subscription? Log in
